# US 2020/0138833 A1 · Chemoprevention of colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138833 A1
- Document ID: US20200138833A1
- Status: Published application
- Kind: A1
- Application number: 16/722,039
- Filed: 2019-12-20
- Published: 2020-05-07
- Earliest claimed: 2012-06-15
- Assignees: Sofar SPA
- Applicants: Sofar SPA
- Inventors: Alexis Grande; Fabrizio Ferrarini; Sandra Parenti
- Web page: https://patentgrep.com/patent/US20200138833A1

## CPC

- A61K 31/606: having amino groups
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In the present invention, a new combination is disclosed comprising (i) 5-aminosalicylic acid (5-ASA) or a derivative thereof, or a pharmacologically acceptable salt thereof, and (ii) a group D vitamin, a derivative thereof, a metabolite or analogue, for use in the prevention and/or treatment of colorectal cancer (CRC). A further aspect of the invention is directed to pharmaceutical compositions comprising said combination together with at least one physiologically acceptable excipient and the use thereof in the prevention and/or in the treatment of the colorectal cancer.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method of preventing or treating colorectal cancer, comprising administering to a patient a daily dose of a combination comprising:
(i) a 5-aminosalicylic acid component, wherein the 5-aminosalicylic acid component comprises 5-aminosalicylic acid or a pharmacologically acceptable salt of 5-aminosalicylic acid; and
(ii) a group D vitamin component, wherein the group D vitamin component is selected from the group consisting of vitamin D3, vitamin D2, 25-hydroxy-vitamin D3 and 1-alpha,25 dihydroxy-vitamin D3;
wherein the combination comprises between 0.5 grams and 5 grams of the 5-aminosalicylic acid component and between 500 international units and 10,000 international units of the group D vitamin component;
wherein the combination does not include calcium; and
wherein the method prevents or treats colorectal cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the combination comprises 5-aminosalicylic acid and vitamin D3.

### Claim 19 (depends on 17)

The method of claim 17, wherein the combination consists of 5-aminosalicylic acid and vitamin D3.

### Claim 20 (depends on 17)

The method of claim 17, wherein the combination comprises approximately 2.4 g of the 5-aminosalicylic component and approximately 2000 IU of the group D vitamin component.

### Claim 21 (depends on 17)

The method of claim 17, wherein the patient is a mammal.

### Claim 22 (depends on 17)

The method of claim 17, wherein the administering step is administered via orally administering, intramuscularly administering, subcutaneously administering or rectally administering.

### Claim 23 (depends on 22)

The method of claim 22, wherein the administering step is administered via orally administering.

### Claim 24 (depends on 17)

The method of claim 17, wherein the administering step is administered by simultaneously administering the 5-aminosalicylic acid component and the group D vitamin component, sequentially administering the 5-aminosalicylic acid component and the group D vitamin component, or separately administering the 5-aminosalicylic acid component and the group D vitamin component.

### Claim 25 (depends on 17)

The method of claim 17, wherein the combination comprises 5-aminosalicylic acid and vitamin D2.

### Claim 26 (depends on 17)

The method of claim 17, wherein the combination comprises 5-amino salicylic acid and 25-hydroxy-vitamin D3.
